Hepatitis C
Pipeline by Development Stage
Drug Modality Breakdown
Hepatitis C is a $3.5B market in mature consolidation, dominated by highly effective direct-acting antivirals with limited new entrant opportunities.
Key Trends
- Market dominated by curative DAA regimens with high barrier to entry
- Patent cliff approaching for legacy products (ISENTRESS 2029, SOVALDI 2031)
- Strong clinical trial activity (1,139 trials) suggests ongoing treatment optimization but limited breakthrough potential
Career Verdict
Moderate career opportunity: stable, specialized market with solid employment but limited growth trajectory and consolidation risk as cures saturate patient populations.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | MAVYRET (glecaprevir and pibrentasvir) | AbbVie | $233M | 7% | Peak | Stable | 10.6yr |
| 2 | SOVALDI (sofosbuvir) | Gilead Sciences | $2M | <1% | Peak | Declining | 5.1yr |
| 3 | ZEPATIER (elbasvir and grazoprevir) | Merck & Co. | $468K | <1% | Peak | Declining | 5.0yr |
Drug Class Breakdown
Market leader, stable revenue
Legacy product, declining sharply
Niche positioning, declining
Career Outlook
StableHepatitis C remains a stable, mature market with solid employment infrastructure but declining growth potential as curative therapies saturate eligible patient populations. The market will support specialized roles in medical affairs, regulatory, and commercial operations, but lacks the innovation upside of emerging areas. Professionals should expect career stability rather than rapid advancement or salary growth.
Breaking In
New professionals should seek roles in Commercial or Medical Affairs at large diversified companies (J&J, AbbVie) where Hepatitis C is one of many franchises, ensuring career mobility if this specialty contracts.
For Experienced Professionals
Experienced professionals with deep virology or hepatology expertise should target Clinical Operations or Medical Affairs leadership roles where disease expertise commands premium compensation ($300K+).
In-Demand Skills
Best For
Hiring Landscape
Hepatitis C generates 7,012 total jobs across 15 companies, with Commercial roles dominating (1,201 jobs, avg $257K) and Clinical Operations offering premium salaries ($307K avg). Hiring concentration in large diversified players (Johnson & Johnson 1,462, AbbVie 1,051, Takeda 1,048) reflects market consolidation; smaller specialists like Gilead Sciences have only 96 open positions. Commercial and Manufacturing roles drive volume, while Clinical Operations and R&D offer technical depth.
By Department
Strong hiring volume in commercial roles but skewed toward large conglomerates; specialist disease knowledge commands premium salaries in Clinical Operations.
On Market (3)
Approved therapies currently available
Competitive Landscape
54 companies ranked by most advanced pipeline stage
+24 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 10,857 patients across 50 trials
HCV Test and Treat Utilizing Simplified HCV Patient Education
The Kentucky Viral Hepatitis Treatment Study
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
HCV Post-Exposure Prophylaxis for Health Care Workers
A Prospective Cohort Study to Improve HCV Care in Dialysis Patients
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk
EBR/GZR for HCV-1b Patients Receiving Hemodialysis
Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)
Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study
Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)
Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant
Maraviroc Efficacy for Hepatitis C
Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care
The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure
Pilot HCV Direct Acting Antiviral Therapy and Metabolism
A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment
Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation
Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4
Timing and Duration of Acute Hepatitis C Treatment
Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
Related Jobs in Infectious Diseases
Clinical Program Manager, Medical Affairs Research Operations
Assoc. Spclst, Engineering
Assoc. Spclst, Engineering
Manager, Regulatory Operations
Senior Director, Medical Affairs Framework
Director, Marketing- Digital Customer Experience
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.